Veracyte (VCYT) Capital Expenditures (2012 - 2026)

Veracyte has reported Capital Expenditures for 15 years, with the latest figure at $2.9 million in Q2 2026.

• Capital Expenditures for Q2 2026 came in at $2.9 million, up 122.32% year-over-year; the trailing twelve-month figure through Jun 2026 was $12.4 million (up 30.62% YoY), and the FY2025 annual result was $9.7 million, down 14.26% from the prior year.
• Capital Expenditures eased to $2.9 million in Q2 2026, from $3.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $4.1 million in Q4 2024 and troughed at $1.3 million in Q2 2025.
• A 5-year average of $2.5 million and a median of $2.5 million in 2022 frame the typical range for Capital Expenditures.
• The widest annual swing landed in 2022, when Capital Expenditures surged 122.59%; it then tumbled 53.57% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $1.9 million in 2022, then surged by 33.39% to $2.5 million in 2023, then surged by 65.84% to $4.1 million in 2024, then declined by 8.72% to $3.8 million in 2025, then decreased by 24.37% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $2.9 million in Q2 2026, $3.0 million in Q1 2026, and $3.8 million in Q4 2025.